JP2009532371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532371A5 JP2009532371A5 JP2009503092A JP2009503092A JP2009532371A5 JP 2009532371 A5 JP2009532371 A5 JP 2009532371A5 JP 2009503092 A JP2009503092 A JP 2009503092A JP 2009503092 A JP2009503092 A JP 2009503092A JP 2009532371 A5 JP2009532371 A5 JP 2009532371A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- composition
- particles
- therapeutic agent
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 20
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 15
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 235000012000 cholesterol Nutrition 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000005847 immunogenicity Effects 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010014172 Factor V Proteins 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78741106P | 2006-03-30 | 2006-03-30 | |
| US78758606P | 2006-03-30 | 2006-03-30 | |
| US60/787,411 | 2006-03-30 | ||
| US60/787,586 | 2006-03-30 | ||
| US86506206P | 2006-11-09 | 2006-11-09 | |
| US60/865,062 | 2006-11-09 | ||
| US87017706P | 2006-12-15 | 2006-12-15 | |
| US60/870,177 | 2006-12-15 | ||
| PCT/US2007/008311 WO2007117469A2 (en) | 2006-03-30 | 2007-03-30 | Compositions of less immunogenic and long-circulating protein-lipid complexes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532371A JP2009532371A (ja) | 2009-09-10 |
| JP2009532371A5 true JP2009532371A5 (enExample) | 2010-05-13 |
| JP5160534B2 JP5160534B2 (ja) | 2013-03-13 |
Family
ID=38581584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503092A Expired - Fee Related JP5160534B2 (ja) | 2006-03-30 | 2007-03-30 | 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7875289B2 (enExample) |
| EP (1) | EP2007357B1 (enExample) |
| JP (1) | JP5160534B2 (enExample) |
| AU (1) | AU2007235463B2 (enExample) |
| CA (1) | CA2660310C (enExample) |
| NZ (1) | NZ572308A (enExample) |
| WO (1) | WO2007117469A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007117469A2 (en) * | 2006-03-30 | 2007-10-18 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| WO2009118658A2 (en) * | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| US20120164189A1 (en) * | 2009-07-07 | 2012-06-28 | Balu-Iyer Sathy V | Lipidic Compositions for Induction of Immune Tolerance |
| US10617640B2 (en) | 2009-07-07 | 2020-04-14 | The Research Foundation For The State University Of New York | Phosphoserine containing compositions for immune tolerance induction |
| CN113876945A (zh) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| US10064922B2 (en) | 2011-10-06 | 2018-09-04 | The Research Foundation For The State University Of New York | Compositions and methods for immune tolerance induction |
| EA201791738A1 (ru) | 2012-05-09 | 2018-03-30 | Вестерн Юниверсити Оф Хелт Сайенсиз | Пролипосомальные композиции тестостерона |
| EP2968474A4 (en) * | 2013-03-13 | 2016-11-23 | Stemetrix Inc | SKIN COMPOSITIONS AND USES |
| WO2015048145A1 (en) | 2013-09-24 | 2015-04-02 | The Research Foundation For The State University Of New York | Compositions and methods for reducing antigen-specific immunogenicity |
| US20230255888A1 (en) * | 2020-07-01 | 2023-08-17 | The Research Foundation For The State University Of New York | Method for preparation of liposomes |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127502A (en) * | 1977-06-10 | 1978-11-28 | Eastman Kodak Company | Stabilizers for reconstituted, lyophilized samples |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4795806A (en) * | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
| US5997864A (en) * | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| KR100217826B1 (ko) * | 1992-04-10 | 1999-09-01 | 나까도미 히로다카 | 리포솜조성물 |
| DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
| DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| CA2181390C (en) | 1995-07-18 | 2001-04-24 | Pankaj Modi | Phospholipid formulations |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| WO1998048837A1 (en) * | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| MXPA00010241A (es) * | 1998-04-27 | 2004-09-06 | Opperbas Holding Bv | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. |
| US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| WO2003013245A1 (en) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| US20040229793A1 (en) * | 2003-02-05 | 2004-11-18 | Balasubramanian Sathyamangalam V. | Compositions and methods for less immunogenic protein formulations |
| US7351688B2 (en) | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
| TW201424770A (zh) * | 2003-02-14 | 2014-07-01 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
| WO2006055352A2 (en) * | 2004-11-08 | 2006-05-26 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
| JP2008544990A (ja) | 2005-06-29 | 2008-12-11 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 低免疫原性蛋白質−脂質複合体に関する組成物および方法 |
| US7875288B2 (en) * | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Method for treating blood coagulation disorders |
| WO2007117469A2 (en) * | 2006-03-30 | 2007-10-18 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
-
2007
- 2007-03-30 WO PCT/US2007/008311 patent/WO2007117469A2/en not_active Ceased
- 2007-03-30 EP EP07754777.6A patent/EP2007357B1/en not_active Not-in-force
- 2007-03-30 US US11/731,648 patent/US7875289B2/en not_active Expired - Fee Related
- 2007-03-30 AU AU2007235463A patent/AU2007235463B2/en not_active Ceased
- 2007-03-30 JP JP2009503092A patent/JP5160534B2/ja not_active Expired - Fee Related
- 2007-03-30 NZ NZ572308A patent/NZ572308A/en not_active IP Right Cessation
- 2007-03-30 CA CA2660310A patent/CA2660310C/en not_active Expired - Fee Related
-
2010
- 2010-12-28 US US12/979,621 patent/US20110123625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532371A5 (enExample) | ||
| JP4545928B2 (ja) | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 | |
| Kedar et al. | Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes | |
| CA2457840C (en) | Hdl for the treatment of stroke and other ischemic conditions | |
| JP7094242B2 (ja) | 低血糖症の治療用経鼻粉末製剤 | |
| JP2012512260A5 (enExample) | ||
| CN102459327A (zh) | 包含表面活性剂蛋白质b(sp-b)和表面活性剂蛋白质c(sp-c)的类似物的改良重构的表面活性剂组合物 | |
| JP2014506884A5 (enExample) | ||
| JPH08512056A (ja) | リポソームの製造法 | |
| RU2000111523A (ru) | Образование пептид/липидного комплекса путем совместной лиофилизации | |
| KR20100015802A (ko) | 개선된 특성을 가지는 재구성된 계면활성제 | |
| JP2010522698A (ja) | 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法 | |
| KR102122088B1 (ko) | 재구성된 폐 계면활성제 | |
| AU2002340825A1 (en) | HDL for the treatment of stroke and other ischemic conditions | |
| Walther et al. | Design of surfactant protein B peptide mimics based on the saposin fold for synthetic lung surfactants | |
| US11951158B2 (en) | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | |
| KR20220005446A (ko) | 리포좀의 생산 방법 | |
| CN88101864A (zh) | 低毒性药物类脂制剂 | |
| Curstedt et al. | New synthetic surfactant–how and when? | |
| JP2002529394A (ja) | 肺サーファクタント組成物を含有する治療セット | |
| CA2527419C (en) | Novel lipid mixtures for synthetic surfactants | |
| Mbagwu et al. | Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits | |
| Holm et al. | Designer surfactants: the next generation in surfactant replacement | |
| CN101389356A (zh) | 药物输送物质 | |
| WO2005105111A1 (ja) | 人工肺サーファクタント組成物およびその使用方法 |